Venetoclax and the future of treatment of multiple myeloma

Описание к видео Venetoclax and the future of treatment of multiple myeloma

Shaji Kumar, MD from the Mayo Clinic, Rochester, MN discusses venetoclax and the future of treatment of multiple myeloma (MM). Venetoclax is an inhibitor of BCL-2, which is generally highly epxressed on multiple myeloma cells. According to Dr Kumar, pre-clinical studies show that venetoclax is active against myeloma cells and he further discusses the results of the Phase I trial of venetoclax as a single agent (NCT01794520) and the Phase I trial of venetoclax with bortezomib and dexamethasone (NCT01794507).
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

Комментарии

Информация по комментариям в разработке